EMA Suspends Leo’s Actinic Keratosis Drug Picato
Also Limits Use Of High-Strength Estradiol Creams
Executive Summary
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
You may also be interested in...
Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
EMA Stands Firm On Estradiol Cream Safety Measure After Doubts Over Impartiality
After a 14-year-old legal dispute, the European Medicines Agency has now repeated its safety review of high-strength estradiol creams for treating vaginal atrophy and says it stands by its original recommendation to place a limit on how long patients should use these products.
International Regulators Plan Roadmap For Collaborative RWE Studies
Experiences during the COVID-19 pandemic are expected to help identify future opportunities for regulatory cooperation on real-world evidence and avoid divergent decision-making for products including advanced therapies and personalized medicines.